Researchers report role of neuronal GPCR gtr-1 in regulating systemic proteostasis and mitigating Aβ toxicity

Researchers discovered that knocking down the neuronal GPCR gtr-1 in C. elegans mitigates Aβ amyloid toxicity and enhances distal protein degradation, revealing a GPCR-mediated neuropeptide signaling pathway that could serve as a systemic therapeutic target for neurodegenerative proteinopathies.

A study published in Science Advances by researchers at The Hebrew University of Jerusalem demonstrated that reducing the expression of gtr-1, a neuronal GPCR in C. elegans, mitigates the toxicity of the Alzheimer's-associated Aβ peptide.

The knockdown of gtr-1 differentially modulated gene expression profiles, specifically altering neuropeptide-coding genes, and altered protein aggregation in worms expressing different proteotoxic proteins.

The researchers also found that gtr-1 knockdown enhances protein degradation, supporting the role of neuropeptides as organism-wide coordinators of proteostasis.

The decline of the proteostasis network and subsequent accumulation of protein aggregates are core drivers of aging and neurodegenerative disorders, including Alzheimer's and Huntington's diseases.

Demonstrating that a neuronal GPCR can govern proteostasis across distal tissues via neuropeptide signaling highlights intertissue communication as a viable lever for systemic therapeutic design.

Targeting upstream neuronal GPCRs that coordinate distal protein quality control networks represents an alternative to directly targeting individual aggregated proteins.

The identified mechanism suggests a novel therapeutic target class—GPCR-modulated neuropeptide signaling—for addressing protein aggregation in neurodegenerative diseases.

If these findings are replicated in mammalian models, they could provide new target pathways for developers in the neurodegeneration space, which currently relies heavily on localized targeting of specific proteins like tau or amyloid-beta.

This discovery could prompt early-stage investment and pipeline exploration into systemic proteostasis regulators and neuropeptide-mediated signaling mechanisms.

Preclinical validation studies evaluating whether mammalian orthologs of the gtr-1 GPCR similarly regulate systemic proteostasis and protein aggregation in rodent models of Alzheimer's disease.